Oral thrush occurs when a yeast infection develops on the inside of mouth and on tongue. This condition is also known as oral candidiasis, oropharyngeal candidiasis, or, simply, thrush. The Candida albicans fungus causes oral thrush. A small amount of this fungus normally lives in your mouth without causing harm. However, when the fungus begins to grow uncontrollably, an infection can develop in mouth. Oral thrush most often occurs in infants and toddlers. It causes white bumps to form on the inner cheeks and tongue. These growths usually go away once treatment is received.
Scope of the Report:This report studies the Oral Thrush market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Oral Thrush market by product type and applications/end industries.
Treatment for oral thrush varies depending on age and overall health. The purpose of treatment is to prevent the growth and spread of the fungus. Once treatment begins, oral thrush usually goes away within a couple of weeks. However, oral thrush may return again in the future. A complete cure is more likely if patients have a healthy immune system and are free of other diseases.
The global Oral Thrush market is valued at xx million USD in 2020 and is expected to reach xx million USD by the end of 2026, growing at a CAGR of xx% between 2020 and 2026.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Oral Thrush.
Europe also play important roles in global market, with market size of xx million USD in 2020 and will be xx million USD in 2026, with a CAGR of xx%.
Market Segment by Companies, this report covers Bayer
Teva Pharmaceuticals
Stellar Pharma
Pfizer
Wockhardt
Ranbaxy Laboratories
Bristol Laboratories
Glenmark Pharmaceuticals
GlaxoSmithKline
Market Segment by Regions, regional analysis covers North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers Pseudomembranous
Erythematous
Hyperplastic
Market Segment by Applications, can be divided into Hospitals & Clinics
Academic And Research Institutes
Frequently Asked Questions
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
- By Type
- By Application
- By Region
- By Country
- By Manufacturer
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
